[L-acetylcarnitine treatment on fragile X patients hyperactive behaviour]

M Calvani1, S D'Iddio, A de Gaetano

  • 1Departamento Científico, Sigma-Tau S.p.A., Rome, Italy.

Revista De Neurologia
|November 26, 2002
PubMed

Insights

L-acetylcarnitine (LAC) significantly reduced hyperactivity in young males with fragile X syndrome (FXS). This pilot study suggests LAC may improve brain function and attention in FXS patients.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability, with hyperactivity affecting nearly all young males.
  • Current treatments for FXS hyperactivity, such as CNS stimulants, often lack efficacy and can worsen attention deficits.

Purpose of the Study:

  • To investigate the potential of L-acetylcarnitine (LAC) as a therapeutic agent for hyperactivity in males with FXS.
  • To evaluate the impact of LAC on brain activity, energy metabolism, and neurotransmitter synthesis in FXS.

Main Methods:

  • A pilot study involved 17 males with FXS treated with LAC for one year.
  • Hyperactivity was assessed using the Conners Abbreviated Parent-Teacher Questionnaire.
  • An ongoing multicenter, double-blind, placebo-controlled study will enroll 160 children with FXS.

Main Results:

  • The pilot study demonstrated a significant reduction in hyperactivity behaviors in FXS males treated with LAC.
  • LAC's proposed mechanisms include modulating energy production, remodeling lipid membranes, and affecting the cholinergic system.

Conclusions:

  • L-acetylcarnitine shows promise in reducing hyperactivity in fragile X syndrome.
  • Further research through a larger, controlled trial is warranted to confirm LAC's efficacy and safety in FXS.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.